ProstACT Global Phase 3 Update: First Patient Dosed, Part 1 Preliminary Data Plans ConfirmedTelix recently announced that its lead prostate cancer candidate TLX591 (lutetium-177 ro...
Many patients believe brand-name drugs are always safer than generics. But that’s a misunderstanding.Drug safety depends on regulation, not branding.What’s the Difference?An orig...